36822-08-9

Basic information

• Product Name: 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONE
• Synonyms: 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONE;AKOS 92531;AKOS B030310;1H-[1]benzothiolo[3,2-d]pyrimidin-4-one
• CAS NO: 36822-08-9
• Molecular Formula: C₁₀H₆N₂OS
• Molecular Weight: 202.23
• Mol File: 36822-08-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: >230°C
• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONE(36822-08-9)
• EPA Substance Registry System: 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONE(36822-08-9)

Safety Data

• Hazardous Substances Data: 36822-08-9(Hazardous Substances Data)

Upstream product

• 394-47-8 2-fluorobenzonitrile 
• 35212-85-2 3-Amino-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 34761-09-6 ethyl 3-aminobenzothiophene-2-carboxylate 
• 3473-63-0 formamidine acetic acid 
• 7716-66-7 3-chloro-1,2-benzisothiazole 
• 99027-28-8 methyl 3-(ethoxymethylene)amino-2-benzothiophenecarboxylate 
• 99027-29-9 3-Aminobenzothiophene-2-carboxylic acid hydrazide 
• 99027-30-2 3-amino<1>benzothieno<3,2-d>pyrimidin-4(3H)-one 
• 77287-34-4 formamide 

Downstream Products

• 36822-09-0 4-chloro-3,4-dihydrobenzo[4,5]thiophene[3,2-d]pyrimidine 
• 1414524-13-2 N-phenylbenzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-11-0 N-(4-methoxybenzyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-09-6 N-(2-methoxybenzyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-07-4 N-(2-methylbenzyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-15-4 N-(2-methylphenyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 41873-33-0 phenylthio-4 benzothieno<3,2-d>pyrimidine 
• 41873-38-5 phenoxy-4 benzothieno<3,2-d>pyrimidine 
• 41873-29-4 benzylthio-4 benzothieno<3,2-d>pyrimidine 
• 41873-24-9 3H-benzyl-3 benzothieno<3,2-d>pyrimidine-thione-4 
• 41873-18-1 3H-benzyl-3 benzothieno<3,2-d>pyrimidone-4 

Relevant articles and documents

Synthesis method of iridium-containing complex

The invention discloses a synthesis method of an iridium-containing complex. The synthesis method is characterized in that a compound Ir (La) (Lb) 2 is prepared through one-step reaction of a substance shown in the specification and La in the presence of one or more solvents or in the absence of solvents. The synthesis method is suitable for an iridium-containing complex containing two same bidentate C-N ligands and one bidentate 1, 3-diketone, 1, 3-dithione or 1, 3-diimine ligand. Compared with the traditional synthesis method, the synthesis method has higher synthesis efficiency, can be carried out under milder reaction conditions, and can realize the synthesis of some complexes which cannot be realized by the traditional method. The iridium-containing complex prepared by the synthesis method is easier to be used in production and manufacturing of organic electroluminescent devices.

DONOR-ACCEPTOR COMPOUNDS WITH NITROGEN CONTAINING HETEROPOLYAROMATICS AS THE ELECTRON ACCEPTOR

Disclosed is a light emitting substance that is used as an emitter in an organic light emitting diode. The light emitting substance includes a donor-acceptor compound having a high triplet energy heteropoly aromatic system. In other words, the donor-acceptor compound includes dibenzofuran, dibenzothiophene, and dibenzoselenophene that are electron acceptors and have multiple nitrogen atoms in one ring. The compound is represented by Chemical Formula 1 below.COPYRIGHT KIPO 2015

PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain fused triaryl amine compounds of the following formula (for convenience, collectively referred to herein as "FTA compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension).